AMG 757: DLL3 targeting, half-life extended bispecific T-cell engager immuno-oncology therapy, in small cell lung cancer

Bookmark and Share
Published: 16 Apr 2021
Views: 2772
Rating:
Save
Dr Luis Paz-Ares - Hospital Universitario 12 de Octubre, Madrid, Spain

Dr Luis Paz-Ares speaks to ecancer about the phase 1 study of AMG 75; a delta-like ligand 3 (DLL3) targeting, half-life extended bispecific T-cell engager immuno-oncology therapy, in small cell lung cancer (SCLC).

Initially, he explains the rationale of this study. Then Dr Paz-Ares discusses the methods and results of this study. He says that AMG 757 showed an acceptable safety profile and preliminary evidence for efficacy in patients with SCLC.

The maximum tolerated dose has not been reached. Dose-finding for monotherapy is ongoing. In the end, Dr Paz-Ares talks about the future impact of this study.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.